
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<P align="right" style="font-size: 10pt"><B>Exhibit&nbsp;99.1</B>



<P align="center" style="font-size: 10pt"><B>EntreMed Announces $14 Million Private Placement with Leading Biotech<BR>
Institutional Investors</B>




<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ROCKVILLE, Md., Dec. 27 /PRNewswire-FirstCall/ &#151; EntreMed, Inc. (Nasdaq:
ENMD), a clinical-stage pharmaceutical company developing therapeutics for the
treatment of cancer and inflammation, today announced that it entered into
definitive agreements to raise $14&nbsp;million in gross proceeds through the
issuance of common stock and warrants to independent institutional
biotechnology investors. Proceeds from the transaction will be used to support
upcoming clinical trials for the Company&#146;s lead oncology product candidate,
Panzem&#174;, and other corporate objectives. The transaction was led by Orbimed
Advisors, Perceptive Life Sciences, Quogue Capital LLC, Domain Associates and
includes other select institutional investors.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EntreMed President and CEO, James S. Burns, commented on the transaction,
&#147;We are pleased to have healthcare investors of this quality among the
shareholders in EntreMed. The proceeds from this transaction provide additional
resources to support our impending Panzem&#174; NCD trials and our preclinical
pipeline.&#148; Mr.&nbsp;Burns continued, &#147;EntreMed will benefit from the active interest
these investors bring in achieving our goal of building a sustainable franchise
in targeted drugs for the treatment of cancer and inflammation.&#148;


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company sold a total of approximately 5.5&nbsp;million shares at $2.55 per
share. The transaction also included the issuance of a number of five-year
warrants equivalent to 20% of the total number of shares of common stock issued
at a 15% premium to the market price of common shares.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EntreMed has agreed to file a registration statement with the SEC within
30&nbsp;days to permit resales of common stock by the investors. Rodman &#038; Renshaw,
LLC served as the placement agent for the transaction. Ferghana Partners also
participated in the placement.


<P align="left" style="font-size: 10pt">About EntreMed



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EntreMed, Inc. (Nasdaq: ENMD) is a clinical-stage pharmaceutical company
developing therapeutic candidates primarily for the treatment of cancer and
inflammation. Panzem&#174; (2-Methoxyestradiol or 2ME2), the Company&#146;s lead drug
candidate, is currently in clinical trials for cancer, as well as in
preclinical development for indications outside of oncology. EntreMed&#146;s goal is
to develop and commercialize new compounds based on the Company&#146;s expertise in
angiogenesis, cell cycle regulation and inflammation &#151; processes vital to the
treatment of cancer and other diseases. The Company&#146;s expertise has also led to
the discovery of new molecules, including analogs of 2ME2, peptides of tissue
factor pathway inhibitor (TFPI), and inhibitors of fibroblast growth factor-2
(FGF-2) and proteinase activated receptor-2 (PAR-2). EntreMed is


<P align="center" style="font-size: 10pt">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="font-size: 10pt">developing these potential drug candidates for either in-house advancement or
external partnering. Additional information about EntreMed is available on the
Company&#146;s website at http://www.entremed.com and in various filings with the
Securities and Exchange Commission.



<P align="left" style="font-size: 10pt">Forward Looking Statements



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This release contains, and other statements that EntreMed may make may
contain, forward-looking statements within the meaning of the Private
Securities Litigation Reform Act with respect to the outlook for expectations
for future financial or business performance, strategies, expectations and
goals. Forward-looking statements are typically identified by words or phrases
such as &#147;believe,&#148; &#147;feel,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;outlook,&#148;
&#147;estimate,&#148; &#147;target,&#148; &#147;assume,&#148; &#147;goal,&#148; &#147;objective,&#148; &#147;plan,&#148; &#147;remain,&#148; &#147;seek,&#148;
&#147;trend,&#148; and variations of such words and similar expressions, or future or
conditional verbs such as &#147;will,&#148; &#147;would,&#148; &#147;should,&#148; &#147;could,&#148; &#147;might,&#148; &#147;can,&#148;
&#147;may,&#148; or similar expressions. Forward-looking statements are subject to
numerous assumptions, risks and uncertainties, which change over time.
Forward-looking statements speak only as of the date they are made, and
EntreMed assumes no duty to update forward-looking statements. Actual results
could differ materially from those currently anticipated due to a number of
factors, including those set forth in EntreMed&#146;s Securities and Exchange
Commission filings under &#147;Risk Factors,&#148; including risks relating to EntreMed&#146;s
need for additional capital and the uncertainty of additional funding; the
early-stage products under development; uncertainties relating to clinical
trials; our success in the further clinical development of Panzem&#174;;
dependence on third parties; future capital needs; and risks relating to the
commercialization, if any, of the Company&#146;s proposed products (such as
marketing, safety, regulatory, patent, product liability, supply, competition
and other risks).


<P align="left" style="font-size: 10pt">CONTACT: Ginny Dunn, Associate Director, Corporate Communications &#038; Investor
Relations, of EntreMed, Inc., &#043;1-240-864-2643.




<P align="center" style="font-size: 10pt">2
</DIV>


</BODY>
</HTML>

